Introduction: Although radiotherapy has been important in the therapy for localized prostate cancer, prostate-specific antigen failure may occur. This study evaluated the effects and side effects of 125I low-dose-rate brachytherapy for patients with postradiation local failure. Patients and Methods: 15 patients who received salvage brachytherapy were analyzed. A prescribed dose of 144 Gy was selected. Median follow-up calculated from the date of salvage brachytherapy was 33.0 months (range 6-51). Results: 5 patients (33.3%) developed prostate-specific antigen failure. The biochemical relapse-free survival rate was 100% at 1 year, 91.7% at 2 years, and 60.2% at 3 years. All acute genitourinary and gastrointestinal adverse events were in grade 1-2 according to Common Terminology Criteria for Adverse Events version 3. As for late adverse events, 1 patient (6.7%) developed grade 3 hematuria at 17 months postsalvage. Conclusions: Although careful patient selection is needed, salvage 125I prostate brachytherapy appears to provide good prostate cancer control with an acceptable rate of complications for patients with local recurrence of prostate cancer after initial radiotherapy.

Keywords:
Salvage 125I brachytherapy, Prostate cancer, Radiotherapy , Recurrence
1.
Pollack A, Hanlon AL, Horwitz EM, Feigenberg SJ, Uzzo RG, Hanks GE: Prostate cancer radiotherapy dose response: an update of the fox chase experience. J Urol 2004;171:1132-1136.
2.
Alicikus ZA, Yamada Y, Zhang Z, Pei X, Hunt M, Kollmeier M, Cox B, Zelefsky MJ: Ten-year outcomes of high-dose, intensity-modulated radiotherapy for localized prostate cancer. Cancer 2011;117:1429-1437.
3.
Shipley WU, Thames HD, Sandler HM, Hanks GE, Zietman AL, Perez CA, Kuban DA, Hancock SL, Smith CD: Radiation therapy for clinically localized prostate cancer: a multi-institutional pooled analysis. JAMA 1999;281:1598-1604.
4.
Wong WW, Buskirk SJ, Schild SE, Prussak KA, Davis BJ: Combined prostate brachytherapy and short-term androgen deprivation therapy as salvage therapy for locally recurrent prostate cancer after external beam irradiation. J Urol 2006;176:2020-2024.
5.
Grossfeld GD, Li YP, Lubeck DP, Broering JM, Mehta SS, Carroll PR: Predictors of secondary cancer treatment in patients receiving local therapy for prostate cancer: data from cancer of the prostate strategic urologic research endeavor. J Urol 2002;168:530-535.
6.
NCCN Clinical Practice Guidelines on Oncology; Prostate Cancer version 1 2011. Available at http://www.nccn.org/professionals/physician_gls/pdf/prostate.pdf. Accessed March 10, 2011.
7.
Nguyen PL, D'Amico AV, Lee AK, Suh WW: Patient selection, cancer control and complications after salvage local therapy for postradiation prostate-specific antigen failure. Cancer 2007;110:1417-1428.
8.
Grado GL, Collins JM, Kriegshauser JS, Balch CS, Grado MM, Swanson GP, Larson TR, Wikes MM, Navickis RJ: Salvage brachytherapy for localized prostate cancer after radiotherapy failure. Urology 1999;53:2-10.
9.
Beyer DC: Permanent brachytherapy as salvage treatment for recurrent prostate cancer. Urology 1999;54:880-883.
10.
Nguyen PL, Chen MH, D'Amico AV, Tempany CM, Steele GS, Albert M, Cormack RA, Carr-Locke DL, Bleday R, Suh WW: Magnetic resonance image-guided salvage brachytherapy after radiation in select men who initially presented with favorable-risk prostate cancer: a prospective phase 2 study. Cancer 2007;110:1485-1492.
11.
Allen GW, Howard AR, Jarrard DF, Ritter MA: Management of prostate cancer recurrences after radiation therapy-brachytherapy as a salvage option. Cancer 2007;110:1405-1416.
12.
Aaronson DS, Yamasaki I, Gottschalk A, Speight J, Hsu IC, Pickett B, Roach M 3rd, Shinohara K: Salvage permanent perineal radioactive-seed implantation for treating recurrence of localized prostate adenocarcinoma after external beam radiotherapy. BJU Int 2009;104:600-604.
13.
Burri RJ, Stone NN, Unger P, Stock RG: Long-term outcome and toxicity of salvage brachytherapy for local failure after initial radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2010;77:1338-1344.
14.
Nath R, Anderson LL, Luxton G, Weaver KA, Williamson JF, Meigooni AS: Dosimetry of interstitial brachytherapy sources: recommendations of the AAPM Radiation Therapy Committee Task Group No. 43. American Association of Physicists in Medicine. Med Phys 1995;22:209-234.
15.
Roach M 3rd, Hanks G, Thames H Jr, Schellhammer P, Shipley WU, Sokol GH, Sandler H: Defining biochemical failure following radiotherapy with or without hormonal therapy in men with clinically localized prostate cancer: recommendations of the RTOG-ASTRO Phoenix Consensus Conference. Int J Radiat Oncol Biol Phys 2006;65:965-974.
16.
Kimura M, Mouraviev V, Tsivian M, Mayes JM, Satoh T, Polascik TJ: Current salvage methods for recurrent prostate cancer after failure of primary radiotherapy. BJU Int 2010;105:191-201.
17.
Levine GN, D'Amico AV, Berger P, Clark PE, Eckel RH, Keating NL Milani RV, et al: Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Androgen-deprivation therapy in prostate cancer and cardiovascular risk: a science advisory from the American Heart Association, American Cancer Society, and American Urological Association: endorsed by the American Society for Radiation Oncology. Circulation 2010;121:833-840.
18.
Chade DC, Shariat SF, Cronin AM, Savage CJ, Karnes RJ, Blute ML, Briganti A, Montorsi F, van der Poel HG, Van Poppel H, Joniau S, Godoy G, Hurtado-Coll A, Gleave ME, Marcos Dall'Oglio M, Srougi M, Scardino PT, Eastham JA: Salvage radical prostatectomy for radiation-recurrent prostate cancer: a multi-institutional collaboration. Eur Urol 2011;60:205-210.
19.
Izawa JI, Madsen LT, Scott SM, Tran JP, McGuire EJ, Von Eschenbach AC, Pisters LL: Salvage cryotherapy for recurrent prostate cancer after radiotherapy: variables affecting patient outcome. J Clin Oncol 2002;20:2664-2716.
20.
Ismail M, Ahmed S, Kastner C, Davies J: Salvage cryotherapy for recurrent prostate cancer after radiation failure: a prospective case series of the first 100 patients. BJU Int 2007;100:760-764.
21.
Ng CK, Moussa M, Downey DB, Chin JL: Salvage cryoablation of the prostate: follow-up and analysis of predictive factors for outcome. J Urol 2007;178:1253-1257.
22.
Pisters LL, Rewcastle JC, Donnelly BJ, Lugnani FM, Katz AE, Jones JS: Salvage prostate cryoablation: initial results from the cryo on-line data registry. J Urol 2008;180:559-563.
23.
Lee B, Shinohara K, Weinberg V, Gottschalk AR, Pouliot J, Roach M 3rd, Hsu IC: Feasibility of high-dose-rate brachytherapy salvage for local prostate cancer recurrence after radiotherapy: the University of California-San Francisco experience. Int J Radiat Oncol Biol Phys 2007;67:1106-1112.
24.
Stone NN, Potters L, Davis BJ, Ciezki JP, Zelefsky MH, Roach M, Fearn PA, Kattan MW, Stock RG: Multicenter analysis of effect of high biologic effective dose on biochemical failure and survival outcomes in patients with Gleason score 7-10 prostate cancer treated with permanent prostate brachytherapy. Int J Radiat Oncol Biol Phys 2009;73:341-346.
25.
Theodorescu D, Gilenwater JY, Koutrouvelis PG: Prostatourethral-rectal fistula after prostate brachytherapy. Cancer 2000;15:258-264.
© 2013 S. Karger AG, Basel
2013
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.